September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Ranibizumab, Bevacizumab, and Aflibercept accumulation and their effect on cell migration and permeability on human ARPE-19 cells
Author Affiliations & Notes
  • Patricia Fernandez
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
    IdiSNA, Navarra Institute for Heatl Research, Pamplona, Spain
  • Manuel Saenz de Viteri
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
  • Sergio Recalde
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
    IdiSNA, Navarra Institute for Heatl Research, Pamplona, Spain
  • Maria Hernandez
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
    IdiSNA, Navarra Institute for Heatl Research, Pamplona, Spain
  • Jaione Bezunartea-Bezunartea
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
    IdiSNA, Navarra Institute for Heatl Research, Pamplona, Spain
  • Elena Alonso
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
  • Maite Moreno-Orduna
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
  • Natalia Aguado
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
  • Idoia Belza
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
  • Alfredo Garcia-Layana
    Experimental Ophthalmology Laboratory, Clinica Universidad de Navarra, Pamplona, Spain
    IdiSNA, Navarra Institute for Heatl Research, Pamplona, Spain
  • Footnotes
    Commercial Relationships   Patricia Fernandez, None; Manuel Saenz de Viteri, None; Sergio Recalde, None; Maria Hernandez, None; Jaione Bezunartea-Bezunartea, None; Elena Alonso, None; Maite Moreno-Orduna, None; Natalia Aguado, None; Idoia Belza, None; Alfredo Garcia-Layana, Alcon (C), Allergan (C), Bayer (C), Novartis (C), Thea Laboratoires (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3363. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Patricia Fernandez, Manuel Saenz de Viteri, Sergio Recalde, Maria Hernandez, Jaione Bezunartea-Bezunartea, Elena Alonso, Maite Moreno-Orduna, Natalia Aguado, Idoia Belza, Alfredo Garcia-Layana; Ranibizumab, Bevacizumab, and Aflibercept accumulation and their effect on cell migration and permeability on human ARPE-19 cells. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3363.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate intracellular accumulation and the effect of bevacizumab, ranibizumab and aflibercept on cellular migration and permeability in a human retinal pigmented epithelium (RPE) cell line.

Methods : Experiments were performed on ARPE-19 cells and anti-VEGF drugs were diluted to a concentration equivalent to their clinical doses. Anti-VEGFs were labeled with Alexa 488 fluorochrome to detect intracellular accumulation by flow cytometry at 1 hour, 1 day and five days. Further, transepithelial electrical resistance (TEER) was measured in transwells at 2, 4, 6, 12 and 24 hours to assess the effect of anti-VEGFs on RPE permeability. Moreover, TEER was also measured at the same time points in the presence of different doses of H2O2 to replicate the oxidative environment observed in Age-related Macular Degeneration (AMD). Wound healing was assessed to determine the effect of the drugs on cellular migration during 72 hours to measured cell covered area by ImageJ software.

Results : The three studied drugs were observed to accumulate inside the cells and they were still detectable five days after being added (p<0.001). A dose-dependent increased in cell permeability was observed in cells treated with H2O2 (p<0.05) that was reverted from the time point of 12 hours and became non-significant. Anti-VEGF drugs did not affect the permeability along time and they were able to reduce the effect of H2O2. Cells treated with anti-VEGF drugs at the beginning of the experiment showed a significant decrease in the damage produced by H2O2 at 4, 6 and 12 hours (p<0.05) with no significant difference between the treatments. On the contrary, when anti-VEGF treatment was used 6 hours after the beginning of the experiment, none of the 3 drugs decreased the deleterious effect of H2O2 in TEER. Anti-VEGF drugs did not affect cellular migration.

Conclusions : Intracellular accumulation of bevacizumab, ranibizumab and aflibercept does not seem to be toxic or affect cell permeability and migration. Moreover, our study suggests that anti-VEGFs have a positive effect on the barrier function of the RPE.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×